^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    QN-302

    i
    Other names: QN-302, QN302, QN 302, SOP1812, SOP 1812, SOP-1812
    Associations

    News

    Trials
    Company:
    Qualigen Therap
    Drug class:
    G4 selective transcription inhibitor, S100P modulator
    Associations

    News

    Trials
    1year
    The G-quadruplex experimental drug QN-302 impairs liposarcoma cell growth by inhibiting MDM2 expression and restoring p53 levels. (PubMed, Nucleic Acids Res)
    In patient-derived xenograft mouse models, QN-302 treatment reduced tumour volume distribution and was well tolerated. We have identified a novel and effective therapeutic strategy to reduce MDM2 expression and promote p53 reactivation in tumours harbouring wild-type TP53, such as WD/DDLPSs.
    Journal
    |
    TP53 (Tumor protein P53) • MDM2 (E3 ubiquitin protein ligase)
    |
    TP53 wild-type
    |
    QN-302
    1year
    The G-quadruplex experimental drug QN-302 impairs liposarcoma cell growth by inhibiting MDM2 expression and restoring p53 levels. (PubMed, Nucleic Acids Res)
    In patient-derived xenograft mouse models, QN-302 treatment reduced tumour volume distribution and was well tolerated. We have identified a novel and effective therapeutic strategy to reduce MDM2 expression and promote p53 reactivation in tumours harbouring wild-type TP53, such as WD/DDLPSs.
    Journal
    |
    TP53 (Tumor protein P53) • MDM2 (E3 ubiquitin protein ligase)
    |
    TP53 wild-type
    |
    QN-302
    over2years
    QN-302 demonstrates opposing effects between i-motif and G-quadruplex DNA structures in the promoter of the S100P gene. (PubMed, Org Biomol Chem)
    QN-302 exhibits exceptional combined synergistic effects compared to many other G-quadruplex and i-motif interacting compounds. This work further emphasises the importance of considering G-quadruplex and i-motif DNA structures as one dynamic system.
    Journal
    |
    S100P (S100 calcium binding protein P)
    |
    QN-302
    over2years
    Trial to Evaluate Safety, PD & PK of IV Study Drug, QN-302, in Pts w/ Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=54, Recruiting, Qualigen Theraputics, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    QN-302
    over2years
    A Phase I Trial Evaluating Safety, PD & PK of IV Study Medication, QN-302, in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=54, Not yet recruiting, Qualigen Theraputics, Inc.
    New P1 trial • Metastases
    |
    QN-302
    almost3years
    The Potent G-Quadruplex-Binding Compound QN-302 Downregulates S100P Gene Expression in Cells and in an In Vivo Model of Pancreatic Cancer. (PubMed, Molecules)
    The experimental drug QN-302 is currently in pre-IND development (as of Q1 2023), and its ability to downregulate S100P protein expression supports a role for this protein as a marker of therapeutic response in pancreatic cancer. These results are also consistent with the hypothesis that the S100P promoter G-quadruplex is a potential therapeutic target in pancreatic cancer at the transcriptional level for QN-302.
    Preclinical • Journal
    |
    S100P (S100 calcium binding protein P)
    |
    QN-302
    almost3years
    The potent quadruplex-binding compound QN-302 down-regulates the S100P gene in in vitro and in vivo models of pancreatic cancer: a potential therapeutic target and biomarker for PDAC (AACR 2023)
    QN-302 is bio-available at therapeutic doses and is well tolerated at these levels in the animal models. It is being developed for clinical evaluation by Qualigen Therapeutics Inc and is currently at the pre-IND stage.
    Preclinical
    |
    S100P (S100 calcium binding protein P)
    |
    QN-302
    almost3years
    A comparison of the activity of the quadruplex-targeting experimental drugs QN-302 and CX-5461 (pidnarulex) in wild-type and gemcitabine-resistant pancreatic cancer cell lines (AACR 2023)
    QN-302 is bio-available at therapeutic doses and is well tolerated at these levels in animal models. It is being developed for clinical evaluation by Qualigen Therapeutics Inc and is currently at the pre-IND stage.
    Preclinical
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    gemcitabine • pidnarulex (CX-5461) • QN-302
    almost4years
    The potent quadruplex-binding compound SOP1812 shows potent anti-proliferative activity in a prostate cancer cell panel and anti-tumor activity in an in vivo model of metastatic prostate cancer (AACR 2022)
    Abiraterone has a GI50 in this line of 4820 nM. SOP1812 is bio-available at therapeutic doses and is well tolerated at these levels in this animal model. It is currently being evaluated as a candidate for clinical development by Qualigen Therapeutics Inc.
    Preclinical
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog)
    |
    abiraterone acetate • QN-302